Control Bionics

Control Bionics Net Debt / EBITDA

The Net Debt to EBITDA of Control Bionics (CBL.AX) as of Oct 16, 2026 is 0.03.

Net Debt / EBITDA

0.03

YoY

754.07%

Last updated:

Net Debt to EBITDA of Control Bionics is 2025 0.03 . Net Debt to EBITDA of Control Bionics was 2024 0.00 . It decreases by 754.07% higher compared to the previous year.

The Control Bionics Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
1.90 AUD
Jan 1, 2019
0.42 AUD
Jan 1, 2020
1.30 AUD
Jan 1, 2021
4.18 AUD
Jan 1, 2022
0.88 AUD
Jan 1, 2023
0.17 AUD
Jan 1, 2024
0.00 AUD
Jan 1, 2025
0.03 AUD
The Control Bionics Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.03+754.07%
0.00-97.78%
0.17-80.53%
0.88-79.04%
4.18+222.38%
1.30+211.67%
0.42-78.15%
1.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Control Bionics Stock analysis

What does Control Bionics do? Control Bionics Ltd, listed on the Australian Securities Exchange under the ticker CBL.AX, is a health care company headquartered in Sydney, Australia. The company focuses on developing and commercializing wireless wearable electromyography (EMG) technology for augmentative and alternative communication (AAC). Founded through an initial public offering on December 7, 2020, Control Bionics targets individuals with communication impairments due to conditions such as motor neuron disease and amyotrophic lateral sclerosis. Its flagship technology, NeuroNode, is a wireless wearable device that detects neural signals transmitted from the brain to skeletal muscles, converting these into EMG output. This output is wirelessly transmitted to a personal computer, enabling users to control speech, email, and text functions. The company’s product portfolio includes NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE. NeuroNode integrates with eye-gaze technology, allowing users to move a cursor on a screen using eye movements, with the NeuroNode functioning as a mouse button. The technology aims to restore communication capabilities for patients with severe motor disabilities, offering a non-invasive solution that leverages existing neural pathways. Control Bionics operates within the health care sector, specifically addressing the needs of patients with neurological conditions that impair verbal or text-based communication. The company’s approach combines wearable technology with real-time data processing to provide accessible communication tools. Its products are designed to enhance user independence and improve quality of life for individuals with limited mobility or speech capabilities. The company’s focus on EMG-based AAC solutions positions it as a specialized player in the health care technology market, targeting a niche but critical segment of patients requiring advanced communication aids. Control Bionics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Control Bionics stock

Net Debt to EBITDA of Control Bionics is 0.03 in 2025.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Control Bionics since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Control Bionics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Control Bionics

All Key Metrics — Control Bionics